Abstract
Background: Understanding SARS-CoV-2 infection in children is necessary to reopen schools safely. Methods: We measured SARS-CoV-2 infection in 320 learners [10.5 ± 2.1 (sd); 7–17 y.o.] at four diverse schools with either remote or on-site learning. Schools A and B served low-income Hispanic learners; school C served many special-needs learners, and all provided predominantly remote instruction. School D served middle- and upper-income learners, with predominantly on-site instruction. Testing occurred in the fall (2020), and 6–8 weeks later during the fall-winter surge (notable for a tenfold increase in COVID-19 cases). Immune responses and mitigation fidelity were also measured. Results: We found SARS-CoV-2 infections in 17 learners only during the surge. School A (97% remote learners) had the highest infection (10/70, 14.3%, p < 0.01) and IgG positivity rates (13/66, 19.7%). School D (93% on-site learners) had the lowest infection and IgG positivity rates (1/63, 1.6%). Mitigation compliance [physical distancing (mean 87.4%) and face-covering (91.3%)] was remarkably high at all schools. Documented SARS-CoV-2-infected learners had neutralizing antibodies (94.7%), robust IFN-γ + T cell responses, and reduced monocytes. Conclusions: Schools can implement successful mitigation strategies across a wide range of student diversity. Despite asymptomatic to mild SARS-CoV-2 infection, children generate robust humoral and cellular immune responses. Impact: Successful COVID-19 mitigation was implemented across a diverse range of schools.School-associated SARS-CoV-2 infections reflect regional rates rather than remote or on-site learning.Seropositive school-aged children with asymptomatic to mild SARS-CoV-2 infections generate robust humoral and cellular immunity.
| Original language | English |
|---|---|
| Pages (from-to) | 1073-1080 |
| Number of pages | 8 |
| Journal | Pediatric Research |
| Volume | 90 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2021 |
Bibliographical note
Publisher Copyright:© 2021, The Author(s).
Funding
NIH NCATS UCI Clinical and Translational Science Award UL1 TR001414; R01AI142841; R21AI143301; Orange County Health Care Agency Research Fund; UCI COVID-19 Research Fund; Support was provided in part by the Robert Wood Johnson Foundation and the National Institute of Allergy and Infectious Diseases, NIH (K08 AI151253-01) to E.R.U.
| Funders | Funder number |
|---|---|
| UCI COVID-19 Research Fund | |
| National Institutes of Health (NIH) | K08 AI151253-01 |
| National Institute of Allergy and Infectious Diseases | R01AI142841, R21AI143301 |
| Robert Wood Johnson Foundation | |
| National Center for Advancing Translational Sciences (NCATS) | UL1TR001414 |
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health